In search of a post-Tecfidera hit for MS, Biogen follows Sanofi, Roche down the BTK path — and bets $125M cash on a drug out of China
Aduhelm may be hogging the spotlight, but behind the scenes, Biogen’s BD team has apparently looked far and wide to spice up the pipeline.
Exhibit A: orelabrutinib, a BTK inhibitor it’s paying $125 million to license from China’s InnoCare Pharma. In particular, Biogen is scoring worldwide rights to develop and commercialize the oral small molecule in multiple sclerosis — the disease where it first made its name.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 113,500+ biopharma pros reading Endpoints daily — and it's free.